Bausch Health Cos (NYSE:BHC) Downgraded by Wall Street Zen to “Buy”

Bausch Health Cos (NYSE:BHC) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Sunday.

BHC has been the subject of a number of other research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Bausch Health Cos in a research report on Monday, December 29th. Barclays started coverage on shares of Bausch Health Cos in a research note on Monday, December 8th. They issued an “equal weight” rating and a $8.00 target price for the company. Truist Financial increased their price target on Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a research report on Wednesday, January 7th. Finally, Raymond James Financial reissued a “market perform” rating on shares of Bausch Health Cos in a research note on Monday, January 26th. Five investment analysts have rated the stock with a Hold rating, According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $8.67.

Bausch Health Cos Stock Up 2.6%

NYSE:BHC opened at $5.99 on Friday. The company has a debt-to-equity ratio of 57.48, a quick ratio of 0.97 and a current ratio of 1.30. The stock has a 50-day simple moving average of $6.70 and a 200 day simple moving average of $6.69. Bausch Health Cos has a one year low of $4.25 and a one year high of $8.69. The company has a market capitalization of $2.22 billion, a price-to-earnings ratio of 6.18 and a beta of 0.42.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd grew its position in shares of Bausch Health Cos by 12,589.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock valued at $34,000 after purchasing an additional 4,910 shares during the period. Northwestern Mutual Wealth Management Co. lifted its stake in Bausch Health Cos by 6,661.3% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock valued at $35,000 after buying an additional 5,329 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Bausch Health Cos by 65.9% during the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after acquiring an additional 3,106 shares in the last quarter. Camelot Portfolios LLC acquired a new stake in shares of Bausch Health Cos during the fourth quarter worth $59,000. Finally, Alpha Wealth Funds LLC bought a new stake in Bausch Health Cos in the 2nd quarter valued at $65,000. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.